Short answer
Harmony Biosciences Holdings, Inc. (HRMY) filed an 8-K current report with the SEC on July 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investors should rely on the referenced earnings exhibit for fiscal-year 2026 performance details.
Harmony Biosciences Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Investors should rely on the referenced earnings exhibit for fiscal-year 2026 performance details
- Disclaimers highlight material risks and no obligation to update projections outside legal requirements
Item 5.02 · Departure/Election of Directors or Officers
- CFO Glenn Reicin departing July 16, 2026 for other career opportunities
- Separation agreement provides employment-agreement severance benefits and pro-rated target bonus
- Senior Vice President and Controller Stephen Mollichella appointed Interim Principal Financial Officer
- Interim CFO brings more than two decades of finance and accounting leadership experience
- Leadership transition creates near-term execution and financial-reporting continuity considerations
Item 7.01 · Regulation FD Disclosure
- July 16, 2026 press release announced previously disclosed officer changes
- Exhibit 99.1 contains the substantive announcement and is incorporated by reference
- Leadership transition may affect execution and investor confidence depending on departing and incoming officers
Item EX-99.1 · Exhibit EX-99.1
- Preliminary Q2 2026 WAKIX revenue approximately $261M, up 30% year over year and 21% sequentially
- Full-year 2026 net revenue guidance reaffirmed at $1.0B-$1.04B, supporting continued commercial momentum
- Full Q2 financial results and business update scheduled for August 4, 2026
- CFO Glenn Reicin resigned July 16 to pursue other opportunities, with no reported disagreement
- SVP and Controller Stephen Mollichella appointed Interim Principal Financial Officer during permanent CFO search
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Harmony Biosciences Holdings, Inc. 8-K filings
Get the next HRMY 8-K as it lands
Follow HRMY for push alerts, or ask the research agent what this filing means.